Mixed trend on the daily chart: below its 200-day average, above its 50-day · 50-day below the 200-day · SuperTrend down since Oct 5 · above the Ichimoku cloud · RSI 52 · MACD below its signal
None of the 29 investors followed here reported a position in TVGN in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a TVGN trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 13, 2026 | Saadi Ryan HChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 8.00M | — |
| Sep 13, 2026 | Desai KirtiChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 750K | — |
| Sep 10, 2026 | Feike Jeffrey LDirector | Stock Award(Grant) at price 0.00 per share. | 75K | — |
| Sep 10, 2026 | Goh Keow LinDirector | Stock Award(Grant) at price 0.00 per share. | 75K | — |
| Sep 10, 2026 | Patton Curtis LDirector | Stock Award(Grant) at price 0.00 per share. | 75K | — |
| Sep 10, 2026 | Podlogar Susan MDirector | Stock Award(Grant) at price 0.00 per share. | 75K | — |
| Sep 10, 2026 | Sordillo Victor JDirector | Stock Award(Grant) at price 0.00 per share. | 75K | — |
| Jul 9, 2026 | Feike Jeffrey LDirector | Stock Award(Grant) at price 0.00 per share. | 40K | — |
| Jul 9, 2026 | Goh Keow LinDirector | Stock Award(Grant) at price 0.00 per share. | 40K | — |
| Jul 9, 2026 | Saadi Ryan HChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 1.22M | — |
| Jul 9, 2026 | Patton Curtis LDirector | Stock Award(Grant) at price 0.00 per share. | 40K | — |
| Jul 9, 2026 | Desai KirtiChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 40K | — |
| Jul 9, 2026 | Podlogar Susan MDirector | Stock Award(Grant) at price 0.00 per share. | 40K | — |
| Jul 9, 2026 | Sordillo Victor JDirector | Stock Award(Grant) at price 0.00 per share. | 40K | — |
| Mar 12, 2026 | Flomenberg NealOfficer | Sale at price 6.40 - 7.75 per share. | 972 | $6.63K |
| Dec 17, 2025 | Saadi Ryan HChief Executive Officer | Stock Gift at price 0.00 per share. | 50K | — |
| Dec 10, 2025 | Saadi Ryan HChief Executive Officer | Stock Gift at price 0.00 per share. | 460K | — |
| Dec 10, 2025 | Desai KirtiChief Financial Officer | Stock Gift at price 0.00 per share. | 300K | — |
| Aug 14, 2025 | Saadi Ryan HChief Executive Officer | Stock Gift at price 0.00 per share. | 20K | — |
| Jun 26, 2025 | Khan SadiqOfficer | Stock Award(Grant) at price 0.00 per share. | 200K | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -8.2 | -13.2 | -65.8 | 46.9 | 19.1 | -28.4 | 24.6 | -1.0 | -5.2 | 7.4 | −57.0% | ||
| 2025 | 44.7 | -14.1 | -15.6 | -4.6 | 25.2 | -3.1 | -20.9 | -8.0 | -13.7 | -20.0 | -29.8 | -24.9 | −67.9% |
| 2024 | -52.7 | 47.4 | -51.7 | -73.3 | -19.2 | -10.5 | -11.5 | -18.4 | -29.5 | 587.5 | -48.2 | -21.4 | −90.7% |
| 2023 | 0.0 | 4.1 | 0.3 | 2.0 | -2.3 | -0.7 | 0.3 | 0.6 | 0.6 | 0.4 | 1.6 | 0.8 | +7.7% |
| 2022 | 0.1 | 0.6 | 0.3 | -0.3 | 0.2 | 0.6 | 0.2 | 0.4 | 0.4 | 0.6 | 0.8 | +4.1% |
No analyst coverage for this instrument.
Tevogen Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment. It is also developing TVGN 920, a preclinical trial drug for treating cervical cancer; TVGN 960, a preclinical trial drug for treating oropharyngeal cancer; TVGN 601, a preclinical trial drug for treating multiple sclerosis; TVGN 930, a preclinical trial drug for treating Epstein-Barr virus associated lymphomas; and TVGN 116, a product candidate targeted at hepatitis B. It also offers artificial intelligence platform for drug development. Tevogen Inc. was formerly known as Tevogen Bio Holdings Inc. and changed its name to Tevogen Inc. in July 2026. The company was incorporated in 2020 and is headquartered in Warren, New Jersey.